Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer

Assessment Status Assessment process complete
Drug Olaparib
Brand Lynparza®
Indication As monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Assessment Process
Rapid review commissioned 19/09/2018
Rapid review completed 01/10/2018
Rapid review outcome The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 16/10/2018
Pre-submission consultation with Applicant 26/11/2018
Full submission received from Applicant 28/06/2019
Preliminary review sent to Applicant 30/09/2019
NCPE assessment re-commenced 25/10/2019
Factual accuracy sent to Applicant 02/12/2019
NCPE assessment re-commenced 12/12/2019
NCPE assessment completed 04/02/2020
NCPE assessment outcome The NCPE recommends that olaparib (Lynparza®), for this indication, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary